Identification
NameGenistein
Accession NumberDB01645  (EXPT01582)
TypeSmall Molecule
GroupsInvestigational
Description

An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.

Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in Felmingia vestita, which is a plant traditionally used against worms. It has also been demonstrated to be effective against intestinal parasites such as the common liver fluke, pork trematode and poultry cestode. [Wikipedia]

Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women. [1]

Genistein can be found in food sources such as tofu, fava beans, soybeans, kudzu, and lupin. It is also present in certain cell cultures and medicinal plants. [Wikipedia]

Structure
Thumb
Synonyms
4',5, 7-Trihydroxyisoflavone
5,7,4'-Trihydroxyisoflavone
Genisteol
Genisterin
External IDs FW-635I-2 / NPI-031L / NSC-36586 / SIPI-807-1
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PrunetolNot Available
SophoricolNot Available
Brand mixturesNot Available
Categories
UNIIDH2M523P0H
CAS number446-72-0
WeightAverage: 270.2369
Monoisotopic: 270.05282343
Chemical FormulaC15H10O5
InChI KeyTZBJGXHYKVUXJN-UHFFFAOYSA-N
InChI
InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
IUPAC Name
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
SMILES
OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O
Pharmacology
Indication

Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Genistein may inhibit cancer cell growth by blocking enzymes required for cell growth.

Genistein may decrease cardiovascular risk in postmenopausal women by interacting with the nuclear estrogen receptors to alter the transcription of cell specific genes. In randomized clinical trials, genistein was seen to increase the ratio of nitric oxide to endothelin and improved flow-mediated endothelium dependent vasodilation in healthy postmenopausal women. [1] In addition, genistein may have beneficial effects on glucose metabolism by inhibiting islet tyrosine kinase activity as well as insulin release dependent on glucose and sulfonylurea. [1]

TargetKindPharmacological actionActionsOrganismUniProt ID
Estrogen receptor betaProteinunknownNot AvailableHumanQ92731 details
DNA topoisomerase 2-alphaProteinunknownNot AvailableHumanP11388 details
Protein-tyrosine kinase 2-betaProteinunknownNot AvailableHumanQ14289 details
Nuclear receptor coactivator 1ProteinunknownNot AvailableHumanQ15788 details
Estrogen receptor alphaProteinunknownNot AvailableHumanP03372 details
Nuclear receptor coactivator 2ProteinunknownNot AvailableHumanQ15596 details
Steroid hormone receptor ERR2Proteinunknown
agonist
HumanO95718 details
Steroid hormone receptor ERR1Proteinunknown
agonist
HumanP11474 details
Nuclear receptor subfamily 1 group I member 2ProteinunknownNot AvailableHumanO75469 details
RAC-alpha serine/threonine-protein kinaseProteinunknownNot AvailableHumanP31749 details
G-protein coupled estrogen receptor 1ProteinunknownNot AvailableHumanQ99527 details
Cytochrome P450 1B1ProteinunknownNot AvailableHumanQ16678 details
Sex hormone-binding globulinProteinunknownNot AvailableHumanP04278 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Genistein
3'-hydroxygenisteinDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
  • Helminthic Microorganisms
  • Parasitic nematodes and other roundworms
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Genistein.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Genistein.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Genistein.Experimental, Illicit
AbciximabGenistein may decrease the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Genistein can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Genistein.Approved
AcenocoumarolGenistein may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Genistein.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Genistein.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Genistein.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Genistein.Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Genistein.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Genistein.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Genistein.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Genistein.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Genistein.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Genistein.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Genistein.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Genistein.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Genistein.Approved, Investigational
AncrodGenistein may decrease the anticoagulant activities of Ancrod.Investigational
AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Genistein.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Genistein.Investigational
Anthrax immune globulin humanGenistein may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanGenistein may decrease the anticoagulant activities of Antithrombin III human.Approved
ApixabanGenistein may decrease the anticoagulant activities of Apixaban.Approved
ArdeparinGenistein may decrease the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanGenistein may decrease the anticoagulant activities of Argatroban.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Genistein.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Genistein.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Genistein.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Genistein.Approved, Investigational
AzithromycinThe metabolism of Genistein can be decreased when combined with Azithromycin.Approved
BecaplerminGenistein may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Genistein.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Genistein.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Genistein.Approved, Investigational
BivalirudinGenistein may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Genistein.Withdrawn
BortezomibThe metabolism of Genistein can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Genistein.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Genistein.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Genistein.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Genistein.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Genistein.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Genistein.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Genistein.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Genistein.Approved
CarbamazepineThe metabolism of Genistein can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Genistein.Approved
CelecoxibCelecoxib may increase the thrombogenic activities of Genistein.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Genistein.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Genistein.Withdrawn
CertoparinGenistein may decrease the anticoagulant activities of Certoparin.Approved
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Genistein.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Genistein.Approved, Vet Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Genistein.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Genistein.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Genistein.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Genistein.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Genistein.Approved
Citric AcidGenistein may decrease the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Genistein.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Genistein.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Genistein.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Genistein.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Genistein.Approved
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Genistein.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Genistein.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Genistein.Approved, Nutraceutical
ClotrimazoleThe metabolism of Genistein can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Genistein.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Genistein.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Genistein.Approved
Conestat alfaGenistein may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Genistein.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Genistein.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Genistein.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Genistein.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Genistein.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Genistein can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Genistein.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Genistein.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Genistein.Approved
DalteparinGenistein may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidGenistein may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Genistein.Approved
DarexabanGenistein may decrease the anticoagulant activities of Ym150.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Genistein.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Genistein.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Genistein.Approved
DeferasiroxThe serum concentration of Genistein can be increased when it is combined with Deferasirox.Approved, Investigational
DesirudinGenistein may decrease the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Genistein.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Genistein.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Genistein.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Genistein.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Genistein.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Genistein.Vet Approved
DextranGenistein may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Genistein may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Genistein may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Genistein may decrease the anticoagulant activities of Dextran 75.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Genistein.Approved, Illicit, Vet Approved
DicoumarolGenistein may decrease the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Genistein.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Genistein.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Genistein.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Genistein.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Genistein.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Genistein.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Genistein.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Genistein.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Genistein.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Genistein.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Genistein.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Genistein.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Genistein.Approved
Edetic AcidGenistein may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Genistein.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Genistein.Approved, Investigational
EnoxaparinGenistein may decrease the anticoagulant activities of Enoxaparin.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Genistein.Approved, Investigational
EquileninThe serum concentration of Equilenin can be increased when it is combined with Genistein.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Genistein.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Genistein.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Genistein.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Genistein.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Genistein.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Genistein.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Genistein.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Genistein.Approved
Ethyl biscoumacetateGenistein may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Genistein.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Genistein.Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Genistein.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Genistein.Approved
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Genistein.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Genistein.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Genistein.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Genistein.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Genistein.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Genistein.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Genistein.Approved
FluindioneGenistein may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Genistein.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Genistein.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Genistein.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Genistein.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Genistein.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Genistein.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Genistein.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Genistein.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Genistein.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Genistein.Approved
Fluticasone propionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Genistein.Approved
FluvoxamineThe metabolism of Genistein can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxGenistein may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumGenistein may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Genistein.Approved, Investigational, Withdrawn
GabexateGenistein may decrease the anticoagulant activities of Gabexate.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Genistein.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Genistein.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Genistein.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Genistein.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Genistein.Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Genistein.Investigational
HeparinGenistein may decrease the anticoagulant activities of Heparin.Approved, Investigational
Human C1-esterase inhibitorGenistein may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Genistein.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Genistein.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Genistein.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Genistein.Approved
IdraparinuxGenistein may decrease the anticoagulant activities of idraparinux.Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Genistein.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Genistein.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Genistein.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Genistein.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Genistein.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Genistein.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Genistein.Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Genistein.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Genistein.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Genistein.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Genistein.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Genistein.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Genistein.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Genistein.Approved
LenalidomideGenistein may increase the thrombogenic activities of Lenalidomide.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Genistein.Approved
LepirudinGenistein may decrease the anticoagulant activities of Lepirudin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Genistein.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Genistein.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Genistein.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Genistein.Approved
LidocaineThe metabolism of Genistein can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Genistein.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Genistein.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Genistein.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Genistein.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Genistein.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Genistein.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Genistein.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Genistein.Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Genistein.Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Genistein.Vet Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Genistein.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Genistein.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Genistein.Approved, Investigational
MexiletineThe metabolism of Genistein can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Genistein.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Genistein.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Genistein.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Genistein.Approved, Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Genistein.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Genistein.Approved, Investigational
NabumetoneNabumetone may increase the thrombogenic activities of Genistein.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Genistein.Approved
NadroparinGenistein may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatGenistein may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Genistein.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Genistein.Approved, Vet Approved
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Genistein.Investigational
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Genistein.Approved
NevirapineThe metabolism of Genistein can be decreased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Genistein.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Genistein.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Genistein.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Genistein.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Genistein.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Genistein.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Genistein.Experimental
Oleoyl-estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Genistein.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Genistein.Approved
OsimertinibThe serum concentration of Genistein can be decreased when it is combined with Osimertinib.Approved
OspemifeneThe risk or severity of adverse effects can be increased when Genistein is combined with Ospemifene.Approved
OtamixabanGenistein may decrease the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Genistein.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Genistein.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Genistein.Approved, Investigational
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Genistein.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Genistein.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Genistein.Approved
Peginterferon alfa-2bThe serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.Approved
Pentosan PolysulfateGenistein may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindioneGenistein may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Genistein can be increased when combined with Phenobarbital.Approved
PhenprocoumonGenistein may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Genistein.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Genistein.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Genistein.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Genistein.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Genistein.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Genistein.Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Genistein.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Genistein.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Genistein.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Genistein.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Genistein.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Genistein.Experimental
PrimidoneThe metabolism of Genistein can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Genistein.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Genistein.Approved, Investigational
Protein CGenistein may decrease the anticoagulant activities of Protein C.Approved
Protein S humanGenistein may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeGenistein may decrease the anticoagulant activities of Protocatechualdehyde.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Genistein.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Genistein.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Genistein.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Genistein.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Genistein.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Genistein.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Genistein.Approved
ReviparinGenistein may decrease the anticoagulant activities of Reviparin.Approved
RifampicinThe metabolism of Genistein can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Genistein.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Genistein.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Genistein.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Genistein.Approved, Investigational
RivaroxabanGenistein may decrease the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Genistein.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Genistein.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Genistein.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Genistein.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Genistein.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Genistein.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Genistein.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Genistein.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Genistein.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Genistein.Approved
SomatotropinThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Genistein.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Genistein.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Genistein.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Genistein.Experimental
SulodexideGenistein may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Genistein.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Genistein.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Genistein.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Genistein.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Genistein.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Genistein.Approved
Tenofovir disoproxilThe metabolism of Genistein can be decreased when combined with Tenofovir.Approved, Investigational
TeriflunomideThe serum concentration of Genistein can be decreased when it is combined with Teriflunomide.Approved
ThalidomideGenistein may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Genistein can be decreased when combined with Theophylline.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Genistein.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Genistein.Approved
TiclopidineThe metabolism of Genistein can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Genistein.Approved
TipranavirGenistein may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Genistein.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Genistein.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Genistein.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Genistein.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Genistein.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Genistein.Approved
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Genistein.Approved, Vet Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Genistein.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Genistein.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Genistein.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Genistein.Investigational, Withdrawn
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Genistein.Approved
VemurafenibThe serum concentration of Genistein can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Genistein.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Genistein.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Genistein.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Genistein.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Genistein.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Genistein.Approved
Vitamin CThe serum concentration of Genistein can be increased when it is combined with Vitamin C.Approved, Nutraceutical
WarfarinGenistein may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranGenistein may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Genistein.Approved
Food InteractionsNot Available
References
Synthesis Reference

J. Mark Weber, Andreas Constantinou, Paul E. Hessler, "Process of preparing genistein." U.S. Patent US5554519, issued June, 1994.

US5554519
General References
  1. Crisafulli A, Altavilla D, Marini H, Bitto A, Cucinotta D, Frisina N, Corrado F, D'Anna R, Squadrito G, Adamo EB, Marini R, Romeo A, Cancellieri F, Buemi M, Squadrito F: Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause. 2005 Mar;12(2):186-92. [PubMed:15772566 ]
  2. Toner E, Brennan GP, Wells K, McGeown JG, Fairweather I: Physiological and morphological effects of genistein against the liver fluke, Fasciola hepatica. Parasitology. 2008 Sep;135(10):1189-203. doi: 10.1017/S0031182008004630. [PubMed:18771609 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCancer of Head and Neck1
1CompletedTreatmentCancers1
1, 2CompletedBasic ScienceCystic Fibrosis (CF)1
1, 2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Rectal Carcinoma1
1, 2RecruitingTreatmentCancers1
1, 2TerminatedBasic ScienceCystic Fibrosis (CF)1
1, 2Unknown StatusTreatmentAdenocarcinomas1
2CompletedPreventionBone destruction / Bone Diseases / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Depressive State / Heart Diseases / Myocardial Ischemia / One to five years postmenopausal1
2CompletedPreventionCancer, Breast1
2CompletedTreatmentAdenocarcinoma, Prostate / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer1
2CompletedTreatmentRecurrent Bladder Cancer / Stage I Bladder Cancer / Stage II Bladder Cancer / Stage III Bladder Cancer1
2Not Yet RecruitingPreventionProstate Cancer1
2Not Yet RecruitingTreatmentBladder Cancers1
2RecruitingSupportive CareChildhood Lymphoma / Childhood Solid Tumors / Ewing's Sarcoma (ES) / Germ Cell Tumors / Lymphoma, Hodgkins / Malignant Lymphomas / Medulloblastoma, Childhood / Medulloblastomas / Neoplasms, Brain / Neuroblastomas / Neuroectodermal Tumors, Primitive / Non-Hodgkin's Lymphoma (NHL) / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Tumors, Solid / Wilms' tumor1
2Unknown StatusBasic ScienceProstatic Neoplasms1
2, 3CompletedTreatmentCoronary Artery Disease1
2, 3CompletedTreatmentMenopause / Osteopenia1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)301.5 dec °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP3.04ALOGPS
logP3.08ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)6.55ChemAxon
pKa (Strongest Basic)-5.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity71.68 m3·mol-1ChemAxon
Polarizability26.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.6785
Caco-2 permeable+0.7002
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.9288
P-glycoprotein inhibitor IINon-inhibitor0.7828
Renal organic cation transporterNon-inhibitor0.9075
CYP450 2C9 substrateNon-substrate0.7672
CYP450 2D6 substrateNon-substrate0.9105
CYP450 3A4 substrateNon-substrate0.6821
CYP450 1A2 substrateInhibitor0.9254
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorInhibitor0.8881
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8009
Ames testNon AMES toxic0.9638
CarcinogenicityNon-carcinogens0.9276
BiodegradationNot ready biodegradable0.8572
Rat acute toxicity3.2988 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9569
hERG inhibition (predictor II)Non-inhibitor0.8917
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-00di-0321900000-1dd6fcaf99898bd949dfView in MoNA
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
GC-MSGC-MS Spectrum - GC-EI-TOFsplash10-00di-0321900000-1dd6fcaf99898bd949dfView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-014l-9600000000-04b546320e268d817276View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00kf-5910000000-7e265d1b4640f882195aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-0v4m-1960000000-7843ec8ae23314f88147View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0290000000-52ec910b223a3688fbc0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0190000000-4045f471e10774927fb0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0090000000-b593f863241cb83cbaa8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0190000000-0cd8d123608bd54f7214View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 5V, Positivesplash10-00di-0090000000-9ce354d07dc39313259bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negativesplash10-001i-0910000000-5eb75a138568fa4ac897View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-0fr6-2920000000-a32f6ae97952bb96de05View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-00di-0290000000-4592d557e739a114cbfaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITTOF (LCMS-IT-TOF) , Positivesplash10-00di-0090000000-14ae481944ad1a1f7ca0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITTOF (LCMS-IT-TOF) , Negativesplash10-014i-0090030000-a3400b0a77da6983528fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - ESI-TOF , NegativeNot Available
LC-MS/MSLC-MS/MS Spectrum - ESI-TOF 20V, NegativeNot Available
LC-MS/MSLC-MS/MS Spectrum - ESI-TOF 50V, NegativeNot Available
LC-MS/MSLC-MS/MS Spectrum - ESI-TOF 40V, NegativeNot Available
LC-MS/MSLC-MS/MS Spectrum - ESI-TOF , NegativeNot Available
LC-MS/MSLC-MS/MS Spectrum - ESI-TOF 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoflavones. These are polycyclic compounds containing a 2-isoflavene skeleton which bears a ketone group at the C4 carbon atom.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassIsoflavonoids
Sub ClassIsoflav-2-enes
Direct ParentIsoflavones
Alternative ParentsHydroxyisoflavonoids / Chromones / Pyranones and derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Vinylogous acids / Heteroaromatic compounds / Oxacyclic compounds / Organooxygen compounds
SubstituentsHydroxyisoflavonoid / Isoflavone / Chromone / Benzopyran / 1-benzopyran / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Pyranone / Phenol / Monocyclic benzene moiety
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors7-hydroxyisoflavones (CHEBI:28088 ) / isoflavones, Isoflavonoids (C06563 ) / Isoflavonoids (LMPK12050218 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by...
Gene Name:
ESR2
Uniprot ID:
Q92731
Uniprot Name:
Estrogen receptor beta
Molecular Weight:
59215.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Uniprot Name:
DNA topoisomerase 2-alpha
Molecular Weight:
174383.88 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Signal transducer activity
Specific Function:
Non-receptor protein-tyrosine kinase that regulates reorganization of the actin cytoskeleton, cell polarization, cell migration, adhesion, spreading and bone remodeling. Plays a role in the regulation of the humoral immune response, and is required for normal levels of marginal B-cells in the spleen and normal migration of splenic B-cells. Required for normal macrophage polarization and migrati...
Gene Name:
PTK2B
Uniprot ID:
Q14289
Uniprot Name:
Protein-tyrosine kinase 2-beta
Molecular Weight:
115873.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcription coactivator activity
Specific Function:
Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription...
Gene Name:
NCOA1
Uniprot ID:
Q15788
Uniprot Name:
Nuclear receptor coactivator 1
Molecular Weight:
156755.44 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Uniprot Name:
Estrogen receptor
Molecular Weight:
66215.45 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcription coactivator activity
Specific Function:
Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues. Critical regulator of glucose metabolism regulation, acts as RORA coactivator to specifically modulate G6PC expression. Involved in the ...
Gene Name:
NCOA2
Uniprot ID:
Q15596
Uniprot Name:
Nuclear receptor coactivator 2
Molecular Weight:
159155.645 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor, may regulate ESR1 transcriptional activity. Induces the expression of PERM1 in the skeletal muscle.
Gene Name:
ESRRB
Uniprot ID:
O95718
Uniprot Name:
Steroid hormone receptor ERR2
Molecular Weight:
56207.085 Da
References
  1. Suetsugi M, Su L, Karlsberg K, Yuan YC, Chen S: Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. [PubMed:14638870 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alp...
Gene Name:
ESRRA
Uniprot ID:
P11474
Uniprot Name:
Steroid hormone receptor ERR1
Molecular Weight:
45509.11 Da
References
  1. Suetsugi M, Su L, Karlsberg K, Yuan YC, Chen S: Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. [PubMed:14638870 ]
  2. Chen S, Ye J, Kijima I, Kinoshita Y, Zhou D: Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol. 2005 May;95(1-5):17-23. [PubMed:15955695 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Uniprot Name:
Nuclear receptor subfamily 1 group I member 2
Molecular Weight:
49761.245 Da
References
  1. Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28. [PubMed:16054614 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein serine/threonine/tyrosine kinase activity
Specific Function:
AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of ...
Gene Name:
AKT1
Uniprot ID:
P31749
Uniprot Name:
RAC-alpha serine/threonine-protein kinase
Molecular Weight:
55686.035 Da
References
  1. Barve V, Ahmed F, Adsule S, Banerjee S, Kulkarni S, Katiyar P, Anson CE, Powell AK, Padhye S, Sarkar FH: Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells. J Med Chem. 2006 Jun 29;49(13):3800-8. [PubMed:16789737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hormone binding
Specific Function:
G-protein coupled estrogen receptor that binds to 17-beta-estradiol (E2) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Stimulates cAMP production, calcium mobilization and tyrosine kinase Src inducing the release of heparin-bound epidermal growth factor (HB-EGF) and subsequent transactivation of the epidermal growth factor receptor (...
Gene Name:
GPER1
Uniprot ID:
Q99527
Uniprot Name:
G-protein coupled estrogen receptor 1
Molecular Weight:
42247.12 Da
References
  1. Thomas P, Dong J: Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):175-9. Epub 2006 Nov 7. [PubMed:17088055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Uniprot Name:
Cytochrome P450 1B1
Molecular Weight:
60845.33 Da
References
  1. Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M: Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol. 2010 Dec 20;23(12):1921-35. doi: 10.1021/tx100286d. [PubMed:21053930 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Uniprot Name:
Sex hormone-binding globulin
Molecular Weight:
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
References
  1. Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin HL, Gonzalez FJ: Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos. 2003 Jul;31(7):924-31. [PubMed:12814970 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Uniprot Name:
Transthyretin
Molecular Weight:
15886.88 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Castro AF, Altenberg GA: Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol. 1997 Jan 10;53(1):89-93. [PubMed:8960067 ]
  2. Versantvoort CH, Rhodes T, Twentyman PR: Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer. 1996 Dec;74(12):1949-54. [PubMed:8980395 ]
  3. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Uniprot Name:
Multidrug resistance-associated protein 1
Molecular Weight:
171589.5 Da
References
  1. Pec MK, Aguirre A, Fernandez JJ, Souto ML, Dorta JF, Villar J: Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002 Nov;10(5):605-8. [PubMed:12373300 ]
  2. Nguyen H, Zhang S, Morris ME: Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci. 2003 Feb;92(2):250-7. [PubMed:12532374 ]
  3. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  4. Versantvoort CH, Rhodes T, Twentyman PR: Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer. 1996 Dec;74(12):1949-54. [PubMed:8980395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Uniprot Name:
ATP-binding cassette sub-family G member 2
Molecular Weight:
72313.47 Da
References
  1. Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004 Jun 15;64(12):4346-52. [PubMed:15205350 ]
  2. Zhang S, Yang X, Morris ME: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004 May;65(5):1208-16. [PubMed:15102949 ]
  3. Perez M, Real R, Mendoza G, Merino G, Prieto JG, Alvarez AI: Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones. J Vet Pharmacol Ther. 2009 Oct;32(5):498-502. doi: 10.1111/j.1365-2885.2008.01050.x. [PubMed:19754918 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:42